Derfor udtrykte PDCO behovet for at udføre flere undersøgelser for præcist at definere den patientpopulation, der bør modtage montelukastnatrium til behandling af mild persisterende astma.
Therefore, the PDCO expressed the need to conduct studies to precisely define the patient population that should receive montelukast sodium for the treatment of mild persistent asthma.